Items

Essential to increase the use of generics in Europe to maintain comprehensive health care? (2012-01)

B. Godman, M. Bennie, C. Baumgartel, L. Sović-Brkičić, T. Burkhardt, J. Furst, K. Garuoliene, M. Gomes, V. Marković Peković, A. Martin, C. Sermet, P. Skiold, M. van Woerkom, L. Vončina, L. Gustafsson, Essential to increase the use of generics in Europe to maintain comprehensive health care?, Farmeconomia. Health economics and therapeutic pathways, Vol. 13, No. 3S, pp. 5 - 20, Jan, 2012
Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs (2013-05)

R. Malmstrom, E. Digene, C. Baumgartel, M. Bennie, I. Bishop, A. Brzezinska, S. Campbell, A. Ferrario, A. Finlayson, J. Furst, K. Garuoliene, M. Gomes, I. Gutierrez-Ibarluzea, A. Haycox, K. Hviding, H. Herholz, M. Hoffman, S. Jan, J. Jones, R. Joppi, M. Kalaba, C. Kvalheim, O. Laius, I. Langner, J. Lonsdale, S. Loov, K. Malinowska, L. McCullagh, K. Paterson, V. Marković Peković, A. Martin, J. Piessnegger, G. Selke, C. Sermet, S. Simoens, C. Tulnay, D. Tomek, L. Vončina, V. Vlahović-Palčevski, J. Wale, M. Wilcock, M. Wladysiuk, M. van Woerkom, C. Zara, L. Gustafsson, Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs, Frontiers in Pharmacology, Vol. 4, pp. 1 - 31, May, 2013
Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs (2014-06)

B. Godman, R. Malmstrom, E. Digene, S. Jayathissa, S. McTaggart, T. Cars, S. Alvarez-Madrazo, C. Baumgartel, A. Brzezinska, A. Bucsics, S. Campbell, I. Eriksson, A. Finlayson, J. Furst, K. Garuoliene, I. Gutierrez-Ibarluzea, K. Hviding, H. Herholz, R. Joppi, R. Joppi, M. Kalaba, O. Laius, K. Malinowska, H. Pedersen, V. Marković Peković, J. Piessnegger, G. Selke, C. Sermet, S. Spillane, D. Tomek, L. Vončina, V. Vlahović-Palčevski, J. Wale, M. Wladysiuk, M. van Woerkom, C. Zara, L. Gustafsson, Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs, Frontiers in Pharmacology, Vol. 5, pp. 1 - 11, Jun, 2014
Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications (2014-06)

B. Godman, B. Wettermark, M. van Woerkom, J. Fraeyman, S. Alvarez-Madrazo, C. Berg, I. Bishop, A. Bucsics, S. Campbell, A. Finlayson, J. Furst, K. Garuoliene, H. Herholz, M. Kalaba, O. Laius, J. Piessnegger, C. Sermet, U. Schwabe, V. Vlahović-Palčevski, V. Marković Peković, L. Vončina, K. Malinowska, C. Zara, L. Gustafsson, Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications, Frontiers in Pharmacology, Vol. 5, pp. 1 - 9, Jun, 2014
Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future (2015-05)

B. Godman, M. Wilcock, A. Martin, S. Bryson, C. Baumgartel, T. Bochenek, W. de Bruyn, L. Sović-Brkičić, M. D'Agata, A. Fogele, A. Coma Fuste, J. Fraeyman, J. Furst, K. Garuoliene, H. Herholz, M. Hoffman, S. Jayathissa, H. Kwon, I. Langner, M. Kalaba, E. Magnusson, E. Anderse Karlssen, O. Laius, V. Marković Peković, E. Magnusson, S. McTaggart, H. Pedersen, J. Piessnegger, A. Ringerud, G. Selke, C. Sermet, K. Schiffers, P. Skiold, D. Tomek, A. Viksna, A. Vitry, C. Zara, R. Malmstrom, Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future, Generics and Biosimilars Initiative Journal, Vol. 4, No. 3, pp. 125 - 135, May, 2015
Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future (2016-07)

W. de Bruyn, C. Ibanez, H. Pedersen, A. Akan, P. Vella Bonanno, L. Sović-Brkičić, A. Bucsics, G. Dedet, J. Eriksen, J. Fadare, J. Furst, G. Gallego, I. Godoi, A. Guerra Junior, H. Gursoz, S. Jan, J. Jones, R. Joppi, S. Kerman, O. Laius, N. Madzikwa, E. Magnusson, M. Maticic, V. Marković Peković, A. Massele, O. Ogunleye, A. O'Leary, J. Piessnegger, C. Sermet, S. Simoens, C. Tiroyakgosi, I. Truter, M. Thyberg, K. Tomek, M. Wladysiuk, S. Vandoros, E. Vural, C. Zara, Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future, Frontiers in Pharmacology, Vol. 7, pp. 1 - 18, Jul, 2016
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways (2016-09)

M. Ermisch, A. Bucsics, P. Vella Bonanno, F. Arickx, A. Bybau, T. Bochenek, M. van der Casteele, E. Digene, J. Furst, K. Garuoliene, M. van der Graff, J. Gulbinovic, A. Haycox, J. Jones, R. Joppi, O. Laius, I. Langner, A. Martin, V. Marković Peković, L. McCullagh, E. Magnusson, E. Nilsen, G. Selke, C. Sermet, S. Simoens, R. Sauremann, A. Schuurman, R. Ramos, V. Vlahović-Palčevski, C. Zara, B. Godman, Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways, Frontiers in Pharmacology, Vol. 7, pp. 1 - 9, Sep, 2016
The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications (2017-08)

A. Ferrario, D. Araja, T. Bochenek, T. Ćatić, D. Danko, M. Dimitrova, J. Furst, I. Greičiute-Kuprijanov, I. Hoxha, A. Jakupi, E. Laidmae, O. Loblova, I. Mardare, V. Marković Peković, D. Meshkov, T. Novakovic, G. Petrova, M. Pomorski, D. Tomek, L. Vončina, A. Haycox, P. Kanavos, P. Vella Bonanno, B. Godman, The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications, PHARMACOECONOMICS, pp. 1 - 15, Aug, 2017
Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation (2017-08)

P. Vella Bonanno, M. Ermisch, B. Godman, A. Martin, J. Van Den Bergh, L. Bezmelnitsyna, A. Bucsics, F. Arickx, A. Bybau, T. Bochenek, M. van der Casteele, E. Diogene, I. Eriksson, J. Furst, M. Gad, I. Greičiute-Kuprijanov, M. van der Graff, J. Gulbinovic, J. Jones, R. Joppi, M. Kalaba, O. Laius, I. Langner, I. Mardare, V. Marković Peković, E. Magnusson, O. Melien, D. Meshkov, G. Petrova, G. Selke, C. Sermet, S. Simoens, A. Schuurman, R. Ramos, J. Rodrigues, C. Zara, E. Zebedin-Brandl, A. Haycox, Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation, Frontiers in Pharmacology, Vol. 8, pp. 1 - 13, Aug, 2017
Systematic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries (2018-01)

T. Bochenek, V. Abilova, A. Alkan, B. Asanin, I. Beriain, Z. Besovic, P. Vella Bonanno, A. Bucsics, M. Davidescu, E. de Weerdt, N. Duborija-Kovacevic, J. Furst, M. Gaga, E. Gailite, J. Gulbinovic, E. Gurpinar, B. Hanko, V. Hargaden, T. Hotvedt, I. Hoxha, I. Huys, A. Inotai, A. Jakupi, H. Jenzer, R. Joppi, O. Laius, M. Lenormand, D. Makridaki, A. Malaj, K. Margus, V. Marković Peković, N. Miljkovic, J. de Miranda, S. Primozic, D. Rajinac, D. schwartz, R. Sebesta, S. Simoens, J. Slaby, L. Sović-Brkičić, T. Tesar, L. Tzirnis, E. Warminska, B. Godman, Systematic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries, Frontiers in Pharmacology, Vol. 8, No. article 942, pp. 1 - 23, Jan, 2018
Recent Initiatives in the Republic of Srpska to Enhance Appropriate Care; Their Influence and Implications (2018-05)

L. Bojanić, V. Marković Peković, R. Škrbić, N. Stojaković, M. Đermanović, J. Bojanić, J. Furst, A. Kurdi, B. Godman, Recent Initiatives in the Republic of Srpska to Enhance Appropriate Care; Their Influence and Implications, Frontiers in Pharmacology, Vol. 9, No. Article 442, pp. 1 - 13, May, 2018
Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets (2018-12)

B. Godman, A. Bucsics, P. Vella Bonanno, W. Oortwijn, C. Rothe, A. Ferrario, S. Bosselli, A. Hill, A. Martin, S. Simoens, A. Kurdi, M. Gad, J. Gulbinovic, A. Timoney, T. Bochenek, A. Salem, I. Hoxha, R. Sauermann, A. Massele, A. Guerra Junior, G. Petrova, Z. Mitkova, G. Achniotou, O. Laius, C. Sermet, G. Selke, V. Kourafalos, J. Yfantopoulos, E. Magnusson, R. Joppi, M. Oluka, H. Kwon, A. Jakupi, F. Kalemeera, J. Fadare, O. Melien, M. Pomorski, M. Wladysiuk, V. Marković Peković, I. Mardare, D. Meshkov, T. Novakovic, J. Furst, D. Tomek, C. Zara, E. diogene, J. Meyer, R. Malmstrom, B. Wettermark, Z. Matsebula, S. Campbell, A. Haycox, Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets, Frontiers in public health, Vol. 6, No. Article 328, pp. 1 - 21, Dec, 2018
Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA (2019-02)

P. Vella Bonanno, A. Bucsics, S. Simoens, A. Martin, W. Oortwijn, J. Gulbinovic, C. Rothe, A. Timoney, A. Ferrario, M. Gad, A. Salem, I. Hoxha, R. Sauremann, M. Kamusheva, M. Dimitrova, G. Petrova, O. Laius, G. Selke, V. Kourafalos, J. Yfantopoulos, E. Magnusson, R. Joppi, A. Jakupi, T. Bochenek, M. Wladysiuk, C. Furtado, V. Marković Peković, I. Mardare, D. Meshkov, J. Furst, D. Tomek, M. Obach Cortadellas, C. Zara, A. Haycox, S. Campbell, B. Godman, Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA, Expert Review of Pharmacoeconomics & Outcome Research, Vol. 19, No. 3, pp. 251 - 261, Feb, 2019
Fixed dose drug combinations - are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries (2020-02)

B. Godman, H. McCabe, T. Leong, D. Mueller, A. Martin, I. Hoxha, J. Mwita, G. Rwegerera, A. Massele, J. Costa, R. Nascimento, L. Lovato, K. Tachkov, P. Milushewa, O. Patrick, L. Niba, O. Laius, I. Sefah, S. Abdulsalim, F. Soleymani, L. Achieng, A. Guantai, M. Oluka, A. Jakupi, K. Logviss, M. Hassali, D. Kibule, F. Kalemeera, M. Mubita, I. Mardare, A. Alrasheedy, J. Furst, D. Tomek, V. Marković Peković, T. Phuong, B. Thanh, A. Kalungia, T. Zaranyika, N. Masuka, I. Olaru, J. Wale, R. Hill, A. Kurdi, A. Timoney, S. Campbell, J. Meyer, Fixed dose drug combinations - are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries, Expert Review of Pharmacoeconomics & Outcome Research, Vol. 20, No. 1, pp. 1 - 26, Feb, 2020
The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures (2021-01)

E. Moorkens, B. Godman, I. Huys, I. Hoxha, A. Malaj, S. Keuerleber, S. Stockinger, S. Mortenhuber, M. Dimitrova, K. Tachkov, L. Vlahović-Palčevski, V. Vlahović-Palčevski, G. Achniotou, J. Slaby, L. Popelkova, K. Kohoutova, D. Bartels, O. Laius, J. Martikainen, G. Selke, V. Kourafalos, E. Magnusson, R. Einarsdottir, R. Adams, R. Joppi, E. Allocati, A. Jakupi, A. Viksna, I. Greičiute-Kuprijanov, P. Vella Bonanno, V. Suttorp, O. Melien, R. Plisko, I. Mardare, D. Meshkov, T. Novakovic, J. Furst, C. Zara, V. Marković Peković, N. Grubiša, G. Befrits, R. Puckett, A. Vulto, The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures, Frontiers in Pharmacology, pp. 1 - 17, Jan, 2021
Variation in the prices of oncology medicines across Europe and the implications for the future (2021-02)

B. Godman, S. Simoens, A. Kurdi, G. Selke, J. Yfantopoulos, A. hill, J. Gulbinovic, A. Martin, A. Timoney, D. Gotham, J. Wale, T. Bochenek, I. Selke Krulichova, E. Allocati, I. Hoxha, A. Malaj, C. Hierlander, A. Nachtnebel, W. Hamelinck, Z. Mitkova, G. Petrova, O. Laius, C. Sermet, I. Langer, R. Joppi, A. Jakupi, E. Poplavski, I. Greičiute-Kuprijanov, P. Vella Bonanno, H. Piepenbrink, V. de Valk, R. Plisko, M. Wladysiuk, V. Marković Peković, I. Mardare, T. Novakovic, M. Parker, J. Furst, D. Tomek, K. Banasova, M. Obach Cortadellas, C. Zara, C. Pontes, M. Juhasz-Haverinen, P. Skiold, S. McTaggart, D. Wong-Rieger, S. Campbell, R. Hill, Variation in the prices of oncology medicines across Europe and the implications for the future, Generics and Biosimilars Initiative Journal, Vol. 10, No. 2, pp. 72 - 82, Feb, 2021
Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications (2021-10)

B. Godman, M. Wladysiuk, S. McTaggart, A. Kurdi, E. Allocati, M. Jakovljevic, F. Kalemeera, I. Hoxha, A. Nachtnebel, R. Sauremann, M. Hinteregger, V. Marković Peković, B. Tubić, G. Petrova, K. Tachkov, J. Slaby, R. Nejezchlebova, I. Selke Krulichova, O. Laius, G. Selke, I. Langer, A. Harsanyi, A. Inotai, A. Jakupi, S. Henkuzens, K. Garuoliene, J. Gulbinovic, P. Vella Bonanno, J. Rutkowski, S. Ingeberg, O. Melien, I. Mardare, J. Furst, S. McBride-Stewart, C. Holmes, C. Pontes, C. Zara, M. Turu Pedrola, M. Hoffman, V. Kourafalos, A. Pisana, R. Banzi, S. Campbell, B. Wettermark, Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications, BioMed Research International, Vol. 2021, No. Article ID 99961, pp. 1 - 16, Oct, 2021
Biosimilars are essential for sustainable healthcare systems; however, key challenges remain as seen with long-acting insulin analogues (2022-03)

B. Godman, B. Tubić, E. Allocati, M. Wladysiuk, S. McTaggart, A. Kurdi, M. Haque, S. McBride-Stewart, F. Kalemeera, A. Massele, I. Hoxha, V. Marković Peković, G. Petrova, K. Tachkov, O. Laius, A. Harsanyi, A. Inotai, A. Jakupi, S. Henkuzens, K. Garuoliene, P. Vella Bonanno, J. Rutkowski, I. Mardare, J. Furst, C. Pontes, C. Zara, M. Turu Pedrola, F. Akter, H. Kwon, A. Martin, R. Banzi, J. Wale, J. Gulbinovic, Biosimilars are essential for sustainable healthcare systems; however, key challenges remain as seen with long-acting insulin analogues, Journal of Applied Pharmaceutical Science, Vol. 12, No. 3, pp. 055 - 072, Mar, 2022
Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries (2022-06)

A. Pisana, B. Wettermark, A. Kurdi, B. Tubić, C. Pontes, C. Zara, E. Van Ganse, G. Petrova, I. Mardare, J. Furst, M. Roig-Izquierdo, O. Melien, P. Vella Bonanno, R. Banzi, V. Marković Peković, Z. Mitkova, B. Godman, Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries, Frontiers in Pharmacology, No. 873556, pp. 1 - 16, Jun, 2022
The Implementation of managed entry agreements in Central and Eastern Europe: Findings and implications for future policies (2017-11)

A. Ferrario, D. Araja, T. Bochenek, T. Catic, M. Dimitrova, J. Furst, L. Greičiute-Kuprijanov, I. Hoxha, E. Laidmae, O. Loblova, I. Mardare, V. Marković Peković, D. Meshkov, P. Kanavos, B. Godman, The Implementation of managed entry agreements in Central and Eastern Europe: Findings and implications for future policies, Abstract Book, pp. 49 - 49, Nov, 2017

Items

Essential to increase the use of generics in Europe to maintain comprehensive health care? (2012-01)

Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs (2013-05)

Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs (2014-06)

Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications (2014-06)

Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future (2015-05)

Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future (2016-07)

Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways (2016-09)

The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications (2017-08)

Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation (2017-08)

Systematic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries (2018-01)

Recent Initiatives in the Republic of Srpska to Enhance Appropriate Care; Their Influence and Implications (2018-05)

Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets (2018-12)

Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA (2019-02)

Fixed dose drug combinations - are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries (2020-02)

The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures (2021-01)

Variation in the prices of oncology medicines across Europe and the implications for the future (2021-02)

Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications (2021-10)

Biosimilars are essential for sustainable healthcare systems; however, key challenges remain as seen with long-acting insulin analogues (2022-03)

Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries (2022-06)

The Implementation of managed entry agreements in Central and Eastern Europe: Findings and implications for future policies (2017-11)